GAMA
PTGX icon

Graticule Asia Macro Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Graticule Asia Macro Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.9K Buy
+260
New +$27.2K ﹤0.01% 165
2017
Q3 		– Sell
-29,027
Closed -$328K – 116
2017
Q2 		$328K Sell
29,027
-2,800
-9% -$29.9K 0.02% 108
2017
Q1 		$408K Hold
31,827
– – 0.02% 115
2016
Q4 		$700K Hold
31,827
– – 0.08% 90
2016
Q3 		$673K Buy
+31,827
New +$435K 0.05% 88

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Graticule Asia Macro Advisors's PTGX Position: Q2 2026 in Review

Graticule Asia Macro Advisors opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 260 shares worth $31.9K. The stake represents ﹤0.01% of the portfolio and ranks #165 among its holdings. This is a return to the name: Graticule Asia Macro Advisors previously reported a position in PTGX as recently as Q2 2017.

Graticule Asia Macro Advisors first reported a position in PTGX in Q3 2016 and has held it in 5 quarters since. The position peaked at $700K in Q4 2016. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Graticule Asia Macro Advisors held 260 shares of Protagonist Therapeutics worth $31.9K as of Q2 2026.
  • Protagonist Therapeutics was a new Graticule Asia Macro Advisors position in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Graticule Asia Macro Advisors's portfolio in Q2 2026, its #165 holding.
  • Graticule Asia Macro Advisors first reported a position in Protagonist Therapeutics in Q3 2016 and has held it in 5 quarters since.
  • Graticule Asia Macro Advisors's Protagonist Therapeutics position peaked at $700K in Q4 2016.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Graticule Asia Macro Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.